Closing the Knowledge Gap: What Community Pharmacists Need to Know About Menopause

In this episode, “Closing the Knowledge Gap: What Community Pharmacists Need to Know About Menopause,” the menopause experts explore the following questions:

1. When you think about community pharmacists, where do you see the most significant knowledge gaps around menopause?
2. Why does it matter that pharmacists are up to speed on the latest menopause literature and guidelines?

The panelists examined how knowledge gaps among community pharmacists around menopause are largely a product of when and how practitioners were trained, with many pharmacists still operating under outdated safety concerns about hormone therapy stemming from the Women's Health Initiative, underscoring the urgent need for continuing education that reflects the current evidence base. The discussion highlighted that pharmacists are uniquely positioned as the most accessible health care professionals, yet many lack the symptom recognition skills needed to identify menopause-related complaints that patients may present indirectly, such as sleep disturbances, anxiety, or purchases of OTC products, rather than explicitly as vasomotor symptoms. The panelists also identified specific real-world clinical errors arising from these gaps, including pharmacists incorrectly flagging the concurrent use of systemic and local vaginal estrogen as an overdose, and unfamiliarity with guideline-based testosterone prescribing for women, making the case that closing these gaps is essential not only for patient safety but also for enabling meaningful physician-pharmacist collaboration in managing complex menopause cases.

Throughout the conversation, the experts offer a comprehensive reflection on the field and the factors that may shape clinicians' approach to care moving forward.

The next episode in this series, “KNDy Neurons Explained: The Brain Science Behind Hot Flashes and New Treatment Targets,” features the panelists advancing their conversation on vasomotor symptoms and menopause and focusing on which patients are best suited for hormone therapy vs newer KNDy receptor–based agents, the neuroscience of how estrogen decline disrupts KNDy neuron activity to produce vasomotor symptoms, and the clinical significance of neurokinin receptor subtypes NK1, NK2, and NK3 as treatment targets.